Format

Send to

Choose Destination
N Engl J Med. 2017 Mar 30;376(13):1211-1222. doi: 10.1056/NEJMoa1700518. Epub 2017 Mar 18.

Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism.

Collaborators (244)

Bianchi A, Brighton T, Carroll P, Chong B, Chunilal S, Coughlin P, Curnow J, Jackson D, Tran H, Ward C, Brodmann M, Kyrle P, Marschang P, Petkov V, Hainaut P, Jordens P, Vandekerkhof J, Verhamme P, Wautrecht J-C, Annichino-Bizzacchi J, van Bellen B, Correa J, Cukier A, Freire A, Pereira A, Porto C, Sacilotto R, Vasconcelos Costa A, Della Siega A, Dolan S, Le Gal G, Gross P, Kahn S, Kassis J, Kovacs M, Pesant Y, Ritchie B, Schulman S, Shivakumar S, Solymoss S, Chang S, Chen R, Chen Z, Chen H, Dai X, Fang B, Fu W, Gao X, Huang J, Lai Y, Li L, Li X, Li Y, Liu J, Liu S, Ma W, Ni S, Qin Z, Shi G, Tian H, Wang S, Wang L, Xiao W, Ying K, Yu G, Yuan Y, Zhang J, Zhang J, Zhang X, Zhang L, Zhu L, Chlumský J, Chochola J, Dunaj M, Kovarova K, Lang P, Matoška P, Podpera I, Spacek R, Stehlikova O, Brønnum-Schou J, Egstrup K, Gislason G, Jeppesen J, May O, Nielsen H, Wiggers H, Achkar A, Aquilanti S, Benhamou Y, Brisot D, Bura-Riviere A, Castella N, Elias A, Falvo N, Ferrari E, Lacroix P, Mahe I, Meneveau N, Messas E, Mismetti P, Montaclair K, Mottier D, Moumneh T, Paleiron N, Parent F, Pernod G, Sanchez O, Schmidt J, Simoneau G, Stephan D, Amann B, Bauersachs R, Beyer-Westendorf J, Blessing E, Czihal M, Espinola-Klein C, Kahrmann G, Licka M, Neumeister A, Schellong S, Boda Z, Farkas K, Gurzo M, Katona A, Riba M, Sipos G, Tóth K, Braester A, Elias M, Gafter-Gvili A, Gavish D, Hussein O, Lishner M, Schiff E, Spectre G, Tzoran-Rozenthal I, Zimlichman R, Ageno W, Agnelli G, Bova C, Garbelotto R, Ghirarduzzi A, Imberti D, Pesavento R, Porreca E, Visonà A, Flota Cervera L, Llamas Esperón G, Rodriguez-Gonzalez D, Solis Morales L, Boersma W, ten Cate H, Erdkamp F, Grifioen-Keijzer A, Marwijk Kooy M, Meijer K, Middeldorp S, Swart-Heikens J, Ten Wolde M, Westerweel P, Braithwaite I, Harper P, Merriman E, Ockelford P, Royle G, Smith M, Ghanima W, Sandset PM, Abola M, Chęciński P, Grzelakowski P, Lewczuk J, Sobkowicz B, Tomkowski W, Abramov I, Chechulov P, Karpenko A, Katelnitskiy I, Kazakov A, Makarova O, Panchenko E, Sergeeva E, Subbotin Y, Suchkov I, Zeltser M, Adler D, Breedt J, Fourie N, Isaacs R, Jacobson B, Siebert H, van Zyl L, Choi J-H, Kang S-M, Kim K-H, Kim H-S, Kim D-I, Min S-K, Park KH, García-Bragado Dalmau F, Gómez Cerezo J, Mirete JCF, Riera A, Del Toro J, Eriksson H, Torstensson I, Banyai M, Baumgartner I, Mazzolai L, Periard D, Righini M, Staub D, Chiang C-E, Chiu K-M, Pai P-Y, Angchaisuksiri P, Chansung K, Öngen G, Tuncay E, Alikhan R, Chetter I, Kesteven P, Nokes T, Bauer K, Comerota A, Elias D, Garcia D, Gibson K, Ginsberg D, Jenkins J, Kingsley E, Lambert R, Lyons R, Pullman J, Shah V, Smith SW, Stein R, Tapson V, Walsh J, Wang T-F, Do Loi D, Do Quang H, Pham N.

Author information

1
From the Thrombosis and Atherosclerosis Research Institute and McMaster University, Hamilton, ON (J.I.W.), and the Department of Medicine, University of Ottawa and the Ottawa Hospital Research Institute, Ottawa (P.S.W.) - both in Canada; Bayer Pharmaceuticals, Leverkusen (A.W.A.L., M.C.S.F., G.H., A.F.P., S.D.B.), Vascular Medicine, Klinikum Darmstadt, Darmstadt (R.B.), the Center for Thrombosis and Hemostasis, University Medical Center Mainz, Mainz (R.B.), and the Department of Hematology, Medical Clinic I, University Hospital Carl Gustav Carus, Dresden (J.B.-W.) - all in Germany; the Department of Epidemiology and Technology Assessment, University of Maastricht, Maastricht, the Netherlands (M.H.P.); the Division of Angiology and Hemostasis and the Faculty of Medicine, University of Geneva, Geneva (H.B.); the Department of Haematology, Prince of Wales Hospital, Sydney (T.A.B.); the Department of Haematology and Oncology, King's College London (J.B.-W.), the Department of Haematological Medicine, Guy's and St. Thomas' Hospitals, King's College Hospital (A.T.C.), and Thrombosis Research Institute and University College London (A.K.K.) - all in London; the University of Washington School of Medicine, Seattle (B.L.D.); Centre d'Investigation Clinique 1408, Sainbiose U1059, Investigation Network on Venous Thromboembolism, Service de Médecine Vasculaire et Thérapeutique, Centre Hospitalo-Universitaire, Hôpital Nord, Saint Etienne, France (H.D.); Janssen Research and Development, Raritan, NJ (L.H.); Hospital Beneficência Portuguesa, São Paulo (B.B.); Vascular Medicine and Hemostasis, University of Leuven, Leuven, Belgium (P.V.); and the Department of Cardiothoracic and Vascular Sciences, Vascular Medicine Unit, University of Padua, Padua, Italy (P.P.).

Abstract

BACKGROUND:

Although many patients with venous thromboembolism require extended treatment, it is uncertain whether it is better to use full- or lower-intensity anticoagulation therapy or aspirin.

METHODS:

In this randomized, double-blind, phase 3 study, we assigned 3396 patients with venous thromboembolism to receive either once-daily rivaroxaban (at doses of 20 mg or 10 mg) or 100 mg of aspirin. All the study patients had completed 6 to 12 months of anticoagulation therapy and were in equipoise regarding the need for continued anticoagulation. Study drugs were administered for up to 12 months. The primary efficacy outcome was symptomatic recurrent fatal or nonfatal venous thromboembolism, and the principal safety outcome was major bleeding.

RESULTS:

A total of 3365 patients were included in the intention-to-treat analyses (median treatment duration, 351 days). The primary efficacy outcome occurred in 17 of 1107 patients (1.5%) receiving 20 mg of rivaroxaban and in 13 of 1127 patients (1.2%) receiving 10 mg of rivaroxaban, as compared with 50 of 1131 patients (4.4%) receiving aspirin (hazard ratio for 20 mg of rivaroxaban vs. aspirin, 0.34; 95% confidence interval [CI], 0.20 to 0.59; hazard ratio for 10 mg of rivaroxaban vs. aspirin, 0.26; 95% CI, 0.14 to 0.47; P<0.001 for both comparisons). Rates of major bleeding were 0.5% in the group receiving 20 mg of rivaroxaban, 0.4% in the group receiving 10 mg of rivaroxaban, and 0.3% in the aspirin group; the rates of clinically relevant nonmajor bleeding were 2.7%, 2.0%, and 1.8%, respectively. The incidence of adverse events was similar in all three groups.

CONCLUSIONS:

Among patients with venous thromboembolism in equipoise for continued anticoagulation, the risk of a recurrent event was significantly lower with rivaroxaban at either a treatment dose (20 mg) or a prophylactic dose (10 mg) than with aspirin, without a significant increase in bleeding rates. (Funded by Bayer Pharmaceuticals; EINSTEIN CHOICE ClinicalTrials.gov number, NCT02064439 .).

PMID:
28316279
DOI:
10.1056/NEJMoa1700518
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center